What Is Actually in Your Artery Wall, and Why the Radiology Report Does Not Tell You

The Scene

The patient in this scene is a composite. Names, ages, and circumstances are changed to protect privacy.

Thomas is 48 years old when he sits down across from me holding a CD of his coronary CTA and a radiology report that says: “Moderate non-obstructive plaque. LAD: 30-50% stenosis. Mild calcification. Minimal plaque: RCA and LCx. IMPRESSION: non-obstructive coronary artery disease.”

Thomas is an engineer. He has read the report six times. He has two questions.

“What exactly is in my artery wall?” he asks.

And: “If the stenosis is only 30 to 50 percent, how did my friend’s artery become 100 percent blocked and he died?”

These are the same question. They are the right question. Most patients who receive a coronary CTA report walk out of radiology with a piece of paper that tells them they have plaque, without any explanation of what plaque is, how it got there, why most of it stays stable and some of it kills, or what they can do about it. The gap between “moderate non-obstructive plaque” and the biology of atherogenesis is where this article lives.

Thomas’s friend, whom I did not treat but whose story Thomas has pieced together, did not die because his artery was 90% blocked. He died because a plaque that was probably only 40-50% stenotic ruptured, exposing its lipid core to the bloodstream, and a clot formed in seconds that produced 100% occlusion. The stenosis degree does not predict rupture. The plaque composition predicts rupture.

What It Is

The Plain-Language Definition

Atherosclerosis is the process by which fatty, inflammatory deposits (plaques) build up inside the walls of arteries. These deposits narrow the artery’s channel over time, reducing blood flow. But their most dangerous property is not narrowing. It is instability. Unstable plaques can rupture or erode, triggering a blood clot that can completely block the artery within minutes. That sudden complete blockage is a heart attack.

Atherosclerosis is not a disease of old age. It begins in childhood. Studies of young soldiers killed in combat in the Korean War found fatty streaks, the earliest form of atherosclerotic lesion, in the coronary arteries of men with a median age of 22 5 / Solid . Autopsy studies of children and adolescents who died from accidents show that fatty streaks are nearly universal by age 10 in populations with typical Western diets 5 / Solid . Atherosclerosis is not something that starts at 50. It starts at 10 and progresses for 40 years before it produces the event that brings the patient to the emergency department.

The Extent of the Disease

Atherosclerosis is the leading cause of death in industrialized nations. In the United States, it is responsible for approximately 700,000 MI-related deaths and 160,000 ischemic stroke deaths annually 5 / Solid . Globally, ischemic heart disease attributable to atherosclerosis causes approximately 9 million deaths per year 5 / Solid 30925-9).

Atherosclerosis is not confined to the coronary arteries. It is a systemic disease. The same process that occurs in coronary arteries occurs in carotid arteries (producing stroke), renal arteries (producing renovascular hypertension), mesenteric arteries (producing intestinal ischemia), and the aorta (producing aortic aneurysm and peripheral arterial disease). A patient with significant coronary atherosclerosis has atherosclerosis elsewhere. A patient with a carotid bruit has atherosclerosis in the coronary circulation. The disease is systemic.

The Mechanism

The Endothelium: Where Atherosclerosis Begins

The innermost layer of every artery is the endothelium: a single layer of cells that lines the arterial lumen. The endothelium is not merely a structural barrier. It is an active organ that produces vasodilatory molecules (nitric oxide, prostacyclin), anticoagulant factors (thrombomodulin, protein C receptor), and inflammatory regulators.

Healthy endothelium is resistant to lipid deposition and leukocyte adhesion. Atherosclerosis begins when endothelial function is impaired.

The primary drivers of endothelial dysfunction are:

• LDL cholesterol (and particularly oxidized LDL): raised circulating LDL penetrates endothelial junctions and accumulates in the subendothelial space (the intima)
• Hypertension: mechanical shear stress and turbulent flow at arterial branch points damage endothelial cells
• Smoking: nicotine and oxidative combustion products produce direct endothelial cytotoxicity
• Hyperglycemia/insulin resistance: advanced glycation end-products and reactive oxygen species impair endothelial NO synthesis
• Hyperhomocysteinemia: oxidative stress and direct endothelial cytotoxicity

The endothelial response to these insults is stereotyped: upregulation of cell adhesion molecules (VCAM-1, ICAM-1, E-selectin) that attract circulating monocytes, and increased permeability that allows LDL to enter the intima.

LDL Entry and Oxidation

Low-density lipoprotein (LDL) is a spherical particle that carries cholesterol through the bloodstream. Its surface protein is ApoB-100. LDL enters the arterial intima by transcytosis through endothelial cells and by passage through inter-endothelial junctions. The rate of intimal LDL accumulation is directly proportional to plasma LDL concentration 5 / Solid .

Once in the intima, LDL is retained by proteoglycans in the extracellular matrix. Retained LDL undergoes oxidative modification by reactive oxygen species produced by endothelial cells, smooth muscle cells, and inflammatory cells. Oxidized LDL (oxLDL) is the key trigger for the inflammatory cascade that drives plaque formation.

The Foam Cell and the Fatty Streak

Oxidized LDL in the intima is recognized by pattern-recognition receptors (toll-like receptors) on endothelial cells, which respond by producing chemokines that recruit circulating monocytes. The monocytes migrate across the endothelium into the intima, where they differentiate into macrophages.

Macrophages ingest oxLDL through scavenger receptors (SR-A, CD36). Unlike LDL receptors, which are downregulated by intracellular cholesterol accumulation, scavenger receptors are not downregulated. Macrophages continue to engulf oxLDL until they are engorged with cholesterol-filled vacuoles. They become foam cells: cells that look microscopically like a mass of bubbles because of the cholesterol droplets filling their cytoplasm.

Collections of foam cells beneath the endothelium produce the fatty streak: the earliest macroscopically visible atherosclerotic lesion. Fatty streaks are present in the aortas of virtually all Americans by age 20, regardless of cardiovascular risk 5 / Solid .

Plaque Formation: From Fatty Streak to Fibrous Cap

The transition from a fatty streak to a clinically significant atherosclerotic plaque takes years to decades, driven by ongoing LDL deposition, chronic macrophage activation, smooth muscle cell migration, and matrix remodeling.

The mature atherosclerotic plaque has three structural components:

The lipid core: A pool of extracellular lipid, predominantly cholesterol esters and free cholesterol, derived from dead and dying foam cells. Foam cells overloaded with cholesterol ultimately undergo apoptosis. When macrophage efferocytosis (clearance of apoptotic cells) fails, secondary necrosis releases the intracellular cholesterol into the extracellular space, creating the necrotic lipid core 5 / Solid .

The fibrous cap: Smooth muscle cells (SMCs), recruited from the medial layer by growth factors (PDGF, TGF-beta), migrate into the intima and produce collagen and extracellular matrix proteins. This collagen scaffolding forms the fibrous cap that covers the lipid core and separates it from the flowing bloodstream. The integrity of the fibrous cap determines whether the plaque is stable or vulnerable 5 / Solid .

The inflammatory infiltrate: T lymphocytes and activated macrophages reside at the shoulder regions of the plaque, the junction between the cap and the adjacent normal intima. These cells produce cytokines (interferon-gamma, TNF-alpha, IL-1) that inhibit SMC collagen synthesis and activate matrix metalloproteinases (MMPs) that degrade existing collagen. This chronic inflammatory activity weakens the fibrous cap.

The Vulnerable Plaque

Not all plaques are equally dangerous. The vulnerable plaque, also called the thin-cap fibroatheroma (TCFA), has specific features that predict rupture:

• Thin fibrous cap (below 65 microns, compared to 150-300 microns in stable plaques)
• Large necrotic lipid core (occupying more than 40% of the plaque volume)
• Dense macrophage infiltrate at the cap shoulder
• Minimal calcification (heavily calcified plaques are paradoxically more stable)
• Positive remodeling (the artery expands outward to accommodate the plaque, maintaining lumen diameter while the plaque grows: this is why severe plaque can exist without stenosis)

The critical insight, which Thomas intuitively grasped in his question, is that the degree of stenosis does not predict rupture risk. In the Virtual Histology IVUS studies and OCT imaging data, the plaques most likely to cause MI are frequently not the most stenotic 5 / Solid . A 40% stenotic plaque with a thin fibrous cap and a large lipid pool is more dangerous than an 80% stenotic plaque covered by a thick fibrous cap with minimal inflammatory infiltrate.

Plaque Rupture: The Mechanism of Acute MI

When a vulnerable plaque ruptures, the thin fibrous cap tears, typically at the shoulder region where macrophage density is highest and collagen synthesis is most severely inhibited. The thrombogenic lipid core is exposed to the flowing bloodstream.

The exposure of the lipid core triggers a cascade:

1. Tissue factor (expressed by foam cells in the lipid core) binds circulating factor VII, initiating the coagulation cascade
2. Platelets adhere to collagen exposed at the rupture site, activate, and aggregate
3. A platelet-rich thrombus forms over the rupture site
4. The coagulation cascade deposits fibrin around the platelet aggregate
5. The thrombus may partially or completely occlude the coronary lumen

Complete occlusion: STEMI (ST-elevation MI), with complete ischemia of the downstream myocardium within 20-30 minutes. Partial occlusion: NSTEMI (non-ST-elevation MI) or unstable angina. Flow-limiting thrombus that spontaneously partially recanalizes: the mechanism of many silent MIs, of which there are approximately 2 for every recognized MI in population studies 5 / Solid .

Plaque Erosion: The Other Mechanism

Plaque erosion is the second major mechanism of acute MI, accounting for approximately 25-40% of acute coronary syndromes, and the predominant mechanism in women under 50 and in younger patients without traditional risk factors 5 / Solid .

In plaque erosion, the thrombus forms over an intact but dysfunctional endothelium, without fibrous cap rupture and without exposure of the lipid core. The mechanism is not as well understood as rupture. Contributing factors include endothelial cell apoptosis from oxidative stress, superficial erosion of proteoglycans by neutrophil-derived enzymes, and local loss of endothelial anticoagulant properties 5 / Solid .

Erosion-related MI tends to occur in younger patients, less calcified plaques, and less severely stenotic segments. The OCT signature is different from rupture: an intact cap with overlying thrombus but no visible lipid pool exposure. This distinction has therapeutic implications: conservative management (anticoagulation alone) rather than immediate stenting may be appropriate for erosion-related ACS in some patients, since the underlying plaque has less structural disruption 4 / Promising .

Calcification: The Paradox

Coronary artery calcification (CAC), measured by CT, is used as a marker of atherosclerotic burden and cardiovascular risk. But calcification within plaque has a paradoxical relationship to instability.

Extensive, dense, smooth calcification is associated with plaque stability. Calcium acts as structural support, making the plaque harder to fracture. Heavily calcified plaques have lower macrophage density and thicker fibrous caps 5 / Solid 00254-6).

Spotty, heterogeneous, or microcalcification is associated with instability. Microcalcifications (calcium deposits below 15 microns in diameter, detectable on OCT but not on CT) are generated by apoptotic smooth muscle cells and macrophages and create stress concentration points in the fibrous cap that predispose to rupture 5 / Solid .

The clinical implication: a high CAC score (indicating extensive calcification) is a powerful marker of atherosclerotic burden and cardiovascular risk, but the calcium itself is not the most dangerous part. The plaque areas between calcium deposits, where the cap may be thin and the lipid pool may be large, are the most vulnerable zones.

The Role of Inflammation

The central role of inflammation in atherosclerosis was definitively established by the CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study), which randomized 10,061 patients with prior MI and raised hsCRP to the IL-1beta inhibitor canakinumab or placebo 5 / Solid . Canakinumab significantly reduced hsCRP and IL-6 without affecting LDL, and reduced the rate of recurrent MI and cardiovascular death by 15% at the 150 mg dose.

CANTOS provided proof of concept that inflammation, independent of LDL, is a causal driver of atherosclerotic events. It also set the stage for the COLCOT trial 5 / Solid and LoDoCo2 trial 5 / Solid , both showing colchicine (1.5 mg/day and 0.5 mg/day, respectively) reduces MACE in patients with established CAD, reinforcing the anti-inflammatory mechanism.

How We Diagnose It

Imaging Atherosclerosis

Coronary CTA: The modality that Thomas’s report came from. CT angiography of the coronary arteries requires iodinated contrast and radiation but provides a direct visualization of the coronary lumen and wall. It can detect stenosis, quantify calcification (CAC scoring is derived simultaneously), characterize plaque morphology (calcified vs non-calcified vs mixed), and identify positive remodeling. The SCOT-HEART trial 5 / Solid 31009-1) established that coronary CTA improved diagnosis and reduced MI compared to standard care in outpatients with chest pain.

Coronary Artery Calcium Scoring (CAC): Non-contrast CT that quantifies calcium in coronary arteries. No iodinated contrast required. The Agatston score correlates with overall atherosclerotic burden across populations. A CAC of 0 identifies extremely low near-term cardiovascular risk; a CAC above 400 indicates high burden 5 / Solid . CAC does not characterize non-calcified plaque.

OCT (Optical Coherence Tomography): Invasive intracoronary imaging that provides the highest resolution currently available for plaque assessment (10-20 micron resolution). Can identify fibrous cap thickness, lipid pool, macrophage infiltrate, and plaque erosion vs rupture in real time during catheterization. The reference standard for vulnerable plaque research.

IVUS (Intravascular Ultrasound): Lower resolution than OCT but can assess plaque volume, composition, and stent apposition. The REVERSAL and ASTEROID trials used IVUS to demonstrate plaque regression with statins 5 / Solid .

The Evidence

Plaque Regression With Statins

The ASTEROID trial (Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis) used IVUS to measure total atheroma volume before and after 24 months of rosuvastatin 40 mg daily 5 / Solid . Mean LDL fell from 130 to 60 mg/dL. Total atheroma volume decreased significantly (median -6.8%). This was the first trial to demonstrate that statin therapy could produce measurable plaque regression in humans. Regression was not complete; the plaques shrank but did not disappear. But the direction of change reversed.

The mechanism: statins reduce LDL, decreasing new cholesterol delivery to the intima. They also have anti-inflammatory effects (reducing endothelial VCAM-1 expression, decreasing macrophage activation) and increase fibrous cap stability by promoting SMC collagen synthesis.

PCSK9 Inhibitors and Plaque Regression

The GLAGOV trial extended the ASTEROID concept to PCSK9 inhibition. 968 patients with CAD already on statins were randomized to evolocumab or placebo for 76 weeks, with IVUS measurement of plaque burden 5 / Solid . Mean LDL fell from 92 to 37 mg/dL with evolocumab. Plaque volume regressed in the evolocumab group and progressed slightly in the placebo group. 64.3% of patients on evolocumab had plaque regression vs 47.3% on placebo.

The Inflammatory Architecture of Vulnerable Plaque

The PROSPECTIVE NATURAL HISTORY STUDY of vulnerable plaque demonstrated, using three-vessel OCT in patients with ACS or stable CAD, that TCFAs (thin-cap fibroatheromas) were common (>40% of patients had at least one) and that TCFAs that progressed to MI over the 1-year follow-up were characterized by higher lipid arc, thinner caps, and greater macrophage density at baseline 5 / Solid .

The Patient Experience

Reading the CTA Report

Thomas’s report says “moderate non-obstructive plaque: LAD 30-50% stenosis.” Here is what this means in plain language:

The main artery supplying the front of his heart has a plaque in the wall that narrows the channel by 30-50%. This is not severe enough to restrict blood flow at rest, and it is probably not severe enough to restrict flow during exercise either (flow-limiting stenosis typically begins above 70% in the LAD and above 50% in the dominant RCA). The plaque is there. It is not causing a current problem. It will continue to accumulate unless treated.

The word “moderate” refers to the degree of stenosis, not to the danger level of the plaque. A “moderate” stenosis can contain a vulnerable thin-cap fibroatheroma. The report cannot tell Thomas this because CTA, unlike OCT, cannot reliably distinguish fibrous cap thickness. What the CTA can tell his cardiologist: the plaque is present, there are both calcified and non-calcified components (the “mixed” pattern), and there is evidence of positive remodeling.

This information demands a response. Thomas needs intensive LDL lowering (targeting LDL below 70 mg/dL, and ideally below 55 mg/dL by European Society of Cardiology criteria for established ASCVD) 5 / Solid . He needs an ApoB measured. He needs blood pressure below 130/80. He may need a statin at maximum tolerated dose. His 10-year ASCVD risk calculator result is less important than what the CTA already shows him.

The Patient’s Fear After a CTA Report

Patients commonly experience significant anxiety after receiving a coronary CTA report that shows any plaque at all. The anxiety is understandable and should be acknowledged. It is also clinically useful: the patient who is alarmed by a finding is the patient who will adhere to treatment.

The correct frame is not reassurance (“it’s not that bad”). The correct frame is explanation and action (“here is what this means biologically, here is what we know about how to prevent progression, and here are the specific steps we are going to take”).

Decisions and Trade-Offs

Who Should Have Coronary CTA or CAC Scoring

Current guidelines support CAC scoring for intermediate-risk patients (10-year ASCVD risk 7.5-20%) where the result may change the decision about whether to start a statin 5 / Solid . A CAC of 0 effectively reclassifies the patient to low near-term risk; a CAC above 100 supports statin initiation.

Coronary CTA is recommended by the SCOT-HEART trial evidence for symptomatic patients with suspected stable angina, where it provides superior diagnostic accuracy to stress testing and identifies patients who would benefit from preventive therapy.

The use of CAC scoring or coronary CTA in purely asymptomatic patients with intermediate or high calculated risk (the “advanced imaging for screening” question) is evolving. The MESA cohort data strongly support CAC as a risk reclassifier, and coronary CTA with plaque characterization is increasingly used in high-risk asymptomatic patients at specialized prevention centers 5 / Solid .

Treating Atherosclerosis Before It Causes an Event

The principal pharmacological interventions for atherosclerosis modification are:

1. Statins: Reduce LDL, reduce plaque volume, stabilize fibrous cap. The evidence for event reduction in both primary and secondary prevention is the strongest in all of preventive cardiology.
2. PCSK9 inhibitors: Achieve greater LDL reduction with additional plaque regression beyond what statins alone achieve.
3. Anti-inflammatory agents: Colchicine (LoDoCo2, COLCOT) reduces MACE by approximately 25-30% in established CAD through plaque stabilization mechanisms.
4. Aspirin: Reduces thrombosis from plaque rupture; indicated for secondary prevention but not universally for primary prevention in lower-risk patients.

Clinical Synthesis

The biology of atherosclerosis is the foundational science behind the clinical thesis here. Every other article in the Plaque lane, and most of the articles in the Pressure lane and Emergencies lane, is a downstream application of what is described in this article.

The clinical argument is specific: atherosclerosis is not a disease that strikes randomly. It is a disease with measurable precursors (LDL, ApoB, Lp(a), hsCRP, insulin resistance, blood pressure) that begin accumulating decades before the first event. The patients who die at 56 from a first MI typically had identifiable and treatable risk factors at 38. The 18-year gap between identifiable risk and fatal event is the window where preventive cardiology operates.

Thomas, with his coronary CTA showing 30-50% stenosis in the LAD at age 48, is in that window. His plaque is visible. It is quantifiable. It is modifiable. What happens over the next 10-20 years depends on whether his risk factors are aggressively managed or whether he is told “come back in two years for a repeat stress test.”

The library, and this article in particular, exists to give Thomas the biological understanding he needs to make the latter conversation impossible. A patient who understands that his thin fibrous cap is held together by collagen that his macrophages are trying to degrade, that his LDL level determines how fast new cholesterol is depositing, and that the difference between 80 mg/dL LDL and 55 mg/dL LDL may be the difference between a ruptured plaque at 61 and an intact plaque at 75, is a patient who takes his statin.

The biology is not academic. The biology is the argument for the medicine.

Extended Evidence Review: The Inflammatory Biology of Atherosclerosis

CANTOS, COLCOT, and the Anti-Inflammatory Trials

The causality of inflammation in atherosclerosis has been tested in multiple randomized trials that target inflammatory pathways independent of lipid levels.

CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study, 2017): 10,061 post-MI patients with hsCRP above 2 mg/L despite statin therapy, randomized to canakinumab (an IL-1beta monoclonal antibody) at 50, 150, or 300 mg quarterly, or placebo. 5 / Solid Canakinumab reduced hsCRP and IL-6 without affecting LDL-C, confirming that anti-inflammatory benefit could be separated from lipid effects.

The 150 mg dose reduced the primary MACE endpoint by 15% (HR 0.85, 95% CI 0.74-0.98) with a significant reduction in nonfatal MI (HR 0.76). Cardiovascular death was reduced. However, canakinumab also increased the risk of fatal infections (HR 1.67 for fatal infection), and this adverse effect prevented its commercial development for cardiovascular indications. The CANTOS result confirmed the causal role of IL-1beta/IL-6 inflammatory signaling in atherosclerotic events.

COLCOT (Colchicine Cardiovascular Outcomes Trial, 2019): 4,745 post-MI patients randomized to colchicine 0.5 mg daily or placebo. 5 / Solid Colchicine reduced the primary cardiovascular endpoint (cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent coronary revascularization) by 23% (HR 0.77, 95% CI 0.61-0.96). Colchicine is an old, inexpensive drug that inhibits microtubule assembly and inflammasome activation (specifically NLRP3 inflammasome, which activates IL-1beta). Unlike canakinumab, colchicine’s anti-inflammatory mechanism does not preferentially impair immune defense against bacteria.

LoDoCo2 (Low-Dose Colchicine 2, 2020): 5,522 patients with chronic coronary artery disease randomized to colchicine 0.5 mg daily or placebo. 5 / Solid Primary endpoint (cardiovascular death, MI, ischemic stroke, or ischemia-driven coronary revascularization) reduced by 31% (HR 0.69, 95% CI 0.57-0.83). Low-dose colchicine received FDA approval in June 2023 for secondary cardiovascular prevention (brand name Lodoco).

Together, CANTOS, COLCOT, and LoDoCo2 provide the strongest causal evidence that inflammatory pathways are active drivers of atherosclerotic cardiovascular events, and that targeting inflammation reduces those events beyond what lipid lowering alone achieves.

Vulnerable Plaque: From Pathology to Clinical Prediction

The “vulnerable plaque” concept: originally articulated by Muller, Fuster, and Libby in the 1990s: holds that most acute MI events result not from slowly progressing severe stenoses but from the rupture or erosion of moderately obstructive, lipid-rich, thin-cap fibroatheromas (TCFAs). 5 / Solid

Pathological features of the vulnerable plaque:

• Thin fibrous cap (below 65 micrometers, defined as TCFA)
• Large necrotic lipid core occupying more than 40% of plaque volume
• Absence of smooth muscle cells and abundance of macrophages in the fibrous cap
• Positive remodeling (outward expansion of the arterial wall, making the plaque not appear obstructive on coronary angiography)
• Intraplaque neovascularization (fragile new vessels that can leak and contribute to plaque instability)

The clinical challenge: standard coronary angiography identifies stenosis (narrowing of the lumen) but misses the most dangerous lesions, which are often non-obstructive and therefore not treated with stenting or bypass surgery. Patients with TCFA lesions at non-obstructive sites have high event rates from unexpected plaque rupture at sites that would not have qualified for revascularization.

Intracoronary imaging modalities that can detect TCFA features:

• Optical coherence tomography (OCT): Near-infrared light source providing 10-micron resolution images of the coronary wall, capable of measuring fibrous cap thickness directly
• Near-infrared spectroscopy (NIRS) with IVUS: Identifies lipid-rich plaques by spectroscopic signal and quantifies the lipid core burden index (LCBI), a measure of plaque lipid content in a coronary segment
• IVUS with virtual histology: Cross-sectional imaging with automated plaque composition analysis

The LRP (Lipid Rich Plaque) study and PROSPECT II study have demonstrated that coronary segments with high LCBI by NIRS-IVUS at the time of STEMI have significantly higher rates of future major adverse cardiovascular events at 2-5 years follow-up compared to low-LCBI segments. 4 / Promising 31047-5) This creates the possibility of plaque-level risk stratification in catheterization laboratory settings: identifying future culprit lesions before they rupture.

Plaque Erosion: The Other Mechanism of ACS

Plaque rupture accounts for approximately 60% of acute MI cases in pathological series. However, approximately 25-30% of acute MI cases, and a higher proportion in young women and non-smokers, occur from plaque erosion: a distinct mechanism in which the fibrous cap remains intact but superficial endothelial cell loss exposes the subendothelial matrix, triggering thrombus formation without plaque rupture. 5 / Solid

Erosion-related ACS tends to occur at plaques with less lipid, more smooth muscle, and more proteoglycan in the superficial intima, and is associated with neutrophil extracellular trap (NET) formation and TLR2 signaling pathway activation. The clinical implications are evolving: erosion-mediated ACS may respond differently to anti-lipid and anti-inflammatory therapies than rupture-mediated ACS. High-intensity statin therapy reduces rupture more than erosion, which may explain part of the residual event rate on maximal therapy.

Extended Mechanism: Cholesterol Crystal Formation and the NLRP3 Inflammasome

How Crystals Trigger Inflammation

When cholesterol accumulates in excess within macrophage-derived foam cells, it can precipitate into cholesterol crystals. These crystals are taken up by macrophages, where they pierce lysosomal membranes and activate the NLRP3 inflammasome: a multiprotein inflammatory complex that cleaves inactive pro-IL-1beta into its active form. 5 / Solid

The released IL-1beta activates endothelial cells and smooth muscle cells, promoting adhesion molecule expression, chemokine production, and macrophage recruitment: accelerating the inflammatory cascade. This mechanism directly links the lipid (cholesterol crystallization) to the inflammation (NLRP3/IL-1beta activation), providing the molecular bridge between hyperlipidemia and plaque inflammation that epidemiology had long suggested existed.

The therapeutic relevance: colchicine, which reached cardiovascular approval in 2023, inhibits microtubule assembly that is required for cholesterol crystal phagocytosis and NLRP3 inflammasome assembly, providing a mechanistic explanation for its anti-atherosclerotic effects. Statins themselves reduce intracellular cholesterol accumulation and, in foam cell models, reduce cholesterol crystal formation: another mechanism linking LDL reduction to plaque stabilization.

Thomas’s CTA Findings in Context

The composite patient Thomas, who presented with an incidental coronary CTA showing non-obstructive plaques at multiple sites, represents the clinical scenario that drives a preventive care model most directly.

Thomas’s CTA finding: soft plaques in the LAD and RCA, with an overall plaque burden score that exceeded the 75th percentile for his age: is not a diagnosis of coronary artery disease in the obstructive sense. His cardiologist might reassure him that “you have no blockages.” But the pathological evidence on vulnerable plaque, and the PROSPECT and PROSPECT II trial data, establish that non-obstructive plaque is the dominant source of future events in young and middle-aged patients.

This clinical approach reframes this: Thomas’s CTA is not a reassurance: it is a quantitative risk measurement. The appropriate response is:

• Initiate high-intensity statin therapy to slow plaque progression and promote fibrous cap thickening
• Measure ApoB to assess cumulative atherogenic particle burden
• Assess hsCRP to evaluate inflammatory component of risk
• Consider low-dose colchicine if hsCRP remains above 2 mg/L despite statin therapy
• Recheck CAC at 3-5 years to monitor progression rate
• Communicate the finding to Thomas as a diagnosis requiring management, not a clean bill of health

This is the prevention thesis in clinical action: atherosclerosis identified before its first clinical event, with tools available to reduce its progression.

Extended Evidence Review: Plaque Erosion and the Non-Rupture Pathway

Two Pathways to Acute Coronary Syndrome

The dominant teaching model of ACS pathogenesis: vulnerable plaque with thin fibrous cap ruptures, exposing the lipid-rich necrotic core, activating platelets and the coagulation cascade, and producing an occlusive thrombus: is accurate for approximately 60-75% of fatal coronary events examined at autopsy. But it is not the only pathway.

Plaque erosion accounts for approximately 25-35% of cases, with higher representation among younger patients and women. In erosion, the thrombus forms on an intact, non-ruptured plaque surface that has lost endothelial coverage. The mechanism involves proteoglycan-rich plaques (high hyaluronan content, accumulation of versican and hyaluronan on the luminal surface) that activate neutrophil extracellular traps (NETs), promoting platelet adhesion and thrombus formation without fibrous cap rupture.

The PROSPECT and PROSPECT II studies (intravascular ultrasound-based prospective follow-up of coronary plaques) confirmed that vulnerable plaque characteristics (thin-cap fibroatheroma, large plaque burden, small luminal area) predicted future coronary events at 3.4-year follow-up, but also showed that a significant proportion of events occurred from plaques that were not classifiable as vulnerable at baseline. 5 / Solid

The clinical implication of erosion: it is more common in younger patients, in women, in diabetic patients, and in smokers. Erosion-related events often occur without pre-existing high-grade stenosis, explaining why sudden cardiac death and acute MI frequently occur without prior angina symptoms. Erosion plaques tend to have less lipid and calcium than rupture-prone plaques: making them harder to detect by current imaging modalities including CT angiography.

Inflammation as a Therapeutic Target: The CANTOS Proof of Concept

The CANTOS trial (Canakinumab Anti-inflammatory Thrombosis Outcome Study) was designed to test whether targeting the NLRP3 inflammasome pathway directly would reduce cardiovascular events, independent of lipid lowering. Canakinumab is a human monoclonal antibody targeting interleukin-1 beta (IL-1b), the pro-inflammatory cytokine activated by the NLRP3 inflammasome when it encounters cholesterol crystals.

CANTOS enrolled 10,061 patients with prior MI and raised hsCRP (above 2 mg/L), randomized to canakinumab 50, 150, or 300 mg subcutaneous every 3 months versus placebo. The 150 mg dose produced a 15% relative reduction in the primary MACE endpoint (HR 0.85, 95% CI 0.74-0.98) with no change in LDL-C. hsCRP fell by approximately 37%. 5 / Solid

CANTOS provided the first direct confirmation that inflammation is causally involved in atherosclerotic event risk, independent of lipid levels. The drug did not become widely used: the 150 mg dose showed a significant increase in fatal infections (HR 1.31 for infection-related mortality), raising the risk-benefit ratio unfavorably except in high-risk patients with markedly raised hsCRP. But the proof of concept was established: target the NLRP3 pathway, reduce events.

Colchicine: The Anti-Inflammatory Advance at Pennies Per Dose

Colchicine, a centuries-old gout drug, works by inhibiting microtubule polymerization and thereby disrupting NLRP3 inflammasome assembly: the same pathway targeted by canakinumab, but through a different mechanism and at a cost of approximately $0.50 per day.

Two large cardiovascular trials confirmed colchicine’s benefit:

COLCOT (2019): 4,745 patients randomized to colchicine 0.5 mg daily or placebo within 30 days of MI. Colchicine reduced the composite of CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization by 23% (HR 0.77, 95% CI 0.61-0.96). 5 / Solid

LoDoCo2 (2020): 5,522 patients with stable chronic coronary artery disease randomized to colchicine 0.5 mg daily or placebo. Colchicine reduced the primary composite (CV death, MI, ischemic stroke, ischemia-driven revascularization) by 31% (HR 0.69, 95% CI 0.57-0.83). 5 / Solid

Colchicine is now FDA-approved for cardiovascular risk reduction in patients with established coronary artery disease (brand name Lodoco, 0.5 mg daily). The most important adverse effect is gastrointestinal (diarrhea, nausea, abdominal pain) in approximately 10% of patients; a non-trivial interaction with simvastatin (colchicine inhibits OATP transporters and slightly increases simvastatin bioavailability) requires monitoring. Drug interactions with CYP3A4 inhibitors (cyclosporine, macrolides) can cause severe colchicine toxicity and require dose reduction or avoidance.

What All Atherosclerosis Science Points Toward

Stop Dying Early’s Plaque lane is grounded in one biological truth: atherosclerosis is neither inevitable nor an isolated mechanical process. It is an inflammatory, immunological, and metabolic disease that begins in the second decade of life (as shown in the Bogalusa Heart Study and PDAY autopsy studies) and whose progression is substantially modifiable by sustained LDL and ApoB reduction, inflammation control, blood pressure improvement, and elimination of smoking.

The biology articles in this lane: from the initial atherosclerosis mechanism through LDL, ApoB, Lp(a), HDL, and triglycerides: build toward a single clinical recommendation: measure completely (ApoB, Lp(a), hsCRP, standard lipids), treat proactively (target ApoB not just LDL-C), and use the full available evidence base (statins, PCSK9 inhibitors, ezetimibe, colchicine, bempedoic acid where indicated) to reduce the atherogenic and inflammatory burden in every high-risk patient.

The patient who stops dying early is the one whose physician measured what matters, treated to target, and revisited the plan at every encounter.

Extended Patient Experience: Communicating Atherosclerosis Risk Without Fatalism

The Biology Is Not Destiny

One of the most important communications tasks in preventive cardiology is helping patients understand that atherosclerosis is both universal and modifiable. When patients learn that atherosclerosis begins in the second decade of life and that virtually all adults have some degree of plaque by middle age, the natural response is either fatalism (“I already have it, so why bother?”) or nihilism (“My genetics will determine my outcome regardless of what I do”).

This program’s response to both reactions is the same: the biology of atherosclerosis is a process, not an event. It has an accelerator: LDL, ApoB, inflammation, blood pressure, smoking, glucose: and it has a brake: every effective intervention reduces the rate of new plaque formation and can produce measurable plaque regression. The SATURN trial (rosuvastatin 40 mg vs atorvastatin 80 mg, IVUS follow-up at 2 years) showed that 55% of patients on high-intensity statin therapy experienced measurable coronary plaque regression, not just stabilization. 5 / Solid

Plaque regression is real. The degree of regression is proportional to the magnitude and duration of LDL-C/ApoB reduction. The patient with known coronary artery disease who achieves LDL-C below 55 mg/dL and ApoB below 65 mg/dL and maintains it for 10 years has measurably less plaque burden than they would have had without therapy. That is not a statistical abstraction: it is the most powerful anti-atherosclerotic intervention available in clinical medicine.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.